A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Clinical trial NCT02082210 · COMPLETED

Trial details

NCT number: NCT02082210
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Hepatocellular Cancer Renal Cell Carcinoma Non-Small Cell Lung Cancer

Start date: 2014-03-07
Primary completion: 2017-12-05
Enrollment: 97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.